Dr. Osipov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd
Los Angeles, CA 90048Phone+1 310-423-6313
Education & Training
Virginia Commonwealth University School of MedicineClass of 2013
Certifications & Licensure
CA State Medical License 2015 - 2027
MD State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma Start of enrollment: 2019 Jun 04
Roles: Contact
Publications & Presentations
PubMed
- 11 citationsExceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.Camille F Ng, John Glaspy, Veronica R Placencio-Hickok, Shant Thomassian, Jun Gong
Journal of the National Comprehensive Cancer Network. 2022-10-01 - 27 citationsDual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.Alex B Blair, Jianxin Wang, John Davelaar, Andrew Baker, Keyu Li
Gastroenterology. 2022-11-01 - 9 citationsRole of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer.Wei Zhou, Adrian Lim, Mouad Edderkaoui, Arsen Osipov, Heshui Wu
International Journal of Biological Sciences. 2024-01-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
